Aardvark Therapeutics stock surges as FDA lifts clinical hold
Aardvark Therapeutics (NASDAQ:AARD) shares rose 21% after the FDA lifted its clinical hold on ARD-101, a drug for Prader-Willi Syndrome. The hold was placed in May 2026 after ECG changes were observed. Aardvark conducted additional studies and plans to resume trials. The company will review trial data in a webcast on October 23, 2026.
How this was made
The 30-second read
Why it matters
The FDA's decision removes a key barrier, allowing the company to resume development and potentially unlock value.
Market read
The news directly explains the 21% share surge and creates a short‑term trading opportunity.
What to watch
Potential for additional regulatory queries or trial enrollment challenges.
Background
Aardvark Therapeutics had paused dosing in its Phase 3 HERO trial after ECG changes triggered a hold in May 2026.
Ticker impact
FDA lifted the clinical hold on Aardvark Therapeutics' ARD-101, prompting a 21% after‑hours share jump.
upward pressure as investors price in resumed trial activity
Regulatory clearance is a material catalyst for biotech stocks; the share price already reacted strongly.
Market effects
May lift sentiment for other rare‑disease biotech firms awaiting FDA decisions.
Limited to US biotech sector; no broader regional effect.
Minor global impact, confined to investors tracking FDA‑related biotech news.
Counterpoint
If the upcoming Phase 3 data disappoint, the rally could be short‑lived.
Key entities
- companyAardvark Therapeutics Inc
Biotech firm developing ARD‑101 for Prader‑Willi Syndrome.
- regulatorFDA
U.S. Food and Drug Administration that lifted the clinical hold.
